Organization
Jiangsu Alphamab Biopharmaceuticals
18 clinical trials
Clinical trial
A Multicenter, Randomized, Double-Blind Phase III Study to Assess the Efficacy and Safety of KN046 Combined With Gemcitabine and Nab-Paclitaxel Versus Placebo Combined With Gemcitabine and Nab-Paclitaxel in First Line Advanced Pancreatic Ductal Adenocarcinoma Subjects (ENREACH-PDAC-01).Status: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
A Single Arm, Open Lable, Dose Escalation Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Preliminary Efficacy of KN026 Monotherapy in Patients With HER2-positive Advanced Malignant Breast and Gastric CancerStatus: Completed, Estimated PCD: 2022-06-30
Clinical trial
Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of JSKN033 in Patients With Advanced or Metastatic Solid Malignant TumorsStatus: Recruiting, Estimated PCD: 2026-03-30
Clinical trial
Phase II Study of Evaluating Efficacy, Safety and Tolerance of KN026 in HER2 Expressing Advanced Gastric/Gastroesophageal Junction CancerStatus: Completed, Estimated PCD: 2022-05-31
Clinical trial
An Open-Label, Multi-Center, Phase 2 Clinical Study to Evaluate Efficacy, Safety, and Tolerability of KN046 in Combination With Axitinib in Subjects With Advanced Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2027-05-29
Clinical trial
A Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of KN052 in Chinese Subjects With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2023-11-14
Clinical trial
A Phase 2, Open-Label, Multi-Center Study to Evaluate Efficacy, Safety and Tolerability of KN046 in Subjects With Thymic CarcinomaStatus: Terminated, Estimated PCD: 2023-07-07
Clinical trial
Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of JSKN003 in Chinese Subjects With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase II Study to Evaluate Efficacy, Safety and Tolerability of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Locally Advanced HER2-positive Breast CancerStatus: Terminated, Estimated PCD: 2023-03-15
Clinical trial
An Open, Multi-center, Ib/II Clinical Trial of KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular CarcinomaStatus: Terminated, Estimated PCD: 2022-05-30
Clinical trial
A Randomized, Open-Label, Active-Controlled, Multi-Center Study to Compare Efficacy, Safety, and Tolerability of KN046 Combined With Lenvatinib Versus Docetaxel in Subjects With Non-Small Cell Lung Cancer After Failure of Anti-PD-(L)1 AgentStatus: Terminated, Estimated PCD: 2023-02-13
Clinical trial
A Phase Ib/II Study to Evaluate Efficacy, Safety and Tolerability of KN046 Monotherapy or in Combination With Nab-paclitaxel in Subjects With Triple-negative Breast CancerStatus: Completed, Estimated PCD: 2022-08-16
Clinical trial
An Open-Label, Multicenter, Dose-Escalation and Expansion Phase Ia/Ib Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KN046 Monotherapy in Subjects With Advanced Solid Tumors and LymphomaStatus: Completed, Estimated PCD: 2023-01-03
Clinical trial
A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KN019 in Patients With Active Rheumatoid Arthritis While Receiving MethotrexateStatus: Completed, Estimated PCD: 2022-07-28
Clinical trial
A Phase II, Open-Label, Multi-Center Study to Evaluate Efficacy, Safety and Tolerability of KN026 in Combination With KN046 in Patients With Locally Advanced Unresectable or Metastatic HER2-positive Solid TumorsStatus: Completed, Estimated PCD: 2022-01-12
Clinical trial
A Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of KN046 in Patients With Advanced Non-small Cell Lung CancerStatus: Terminated, Estimated PCD: 2022-07-30
Clinical trial
Phase II Study of Efficacy and Safety Evaluation of KN026 Monotherapy or Combination Therapy in Patients With HER2 Expressing or Positive Metastatic Breast CancerStatus: Active (not recruiting), Estimated PCD: 2021-05-27
Clinical trial
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Trial Of JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer SubjectsStatus: Not yet recruiting, Estimated PCD: 2025-04-01